Does the media favor RARE or KRYS?

In the previous week, Ultragenyx Pharmaceutical had 7 more articles in the media than Krystal Biotech. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 5 mentions for Krystal Biotech. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Krystal Biotech's score of 1.10 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RGC or RARE?

Ultragenyx Pharmaceutical has a consensus price target of $59.56, suggesting a potential upside of 107.10%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ultragenyx Pharmaceutical 1 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.82

Which has stronger earnings and valuation, RGC or RARE?

Regencell Bioscience has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Ultragenyx Pharmaceutical $673M 4.21 -$575M -$6.11 N/A

Does the media refer more to RARE or CYTK?

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Cytokinetics. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 9 mentions for Cytokinetics. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Cytokinetics' score of 0.97 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RARE or ABVX?

In the previous week, Ultragenyx Pharmaceutical had 5 more articles in the media than Abivax. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 7 mentions for Abivax. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Abivax's score of 0.28 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor QGEN or RARE?

In the previous week, Ultragenyx Pharmaceutical had 10 more articles in the media than Qiagen. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 2 mentions for Qiagen. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Qiagen's score of 0.37 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ultragenyx Pharmaceutical (RARE) Competitors

$28.76 -0.27 (-0.93%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$29.16 +0.40 (+1.41%)

As of 06/23/2026 07:25 PM Eastern

Compare

RARE vs. KRYS, RGC, CYTK, ABVX, and QGEN

Should you buy Ultragenyx Pharmaceutical stock or one of its competitors? MarketBeat compares Ultragenyx Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ultragenyx Pharmaceutical include Krystal Biotech (KRYS), Regencell Bioscience (RGC), Cytokinetics (CYTK), Abivax (ABVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Ultragenyx Pharmaceutical has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical currently has a consensus price target of $59.56, suggesting a potential upside of 107.10%. Krystal Biotech has a consensus price target of $340.56, suggesting a potential upside of 0.10%. Given Ultragenyx Pharmaceutical's higher possible upside, equities analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Ultragenyx Pharmaceutical had 7 more articles in the media than Krystal Biotech. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 5 mentions for Krystal Biotech. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Krystal Biotech's score of 1.10 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a net margin of 53.92% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Krystal Biotech's return on equity of 19.25% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Krystal Biotech	53.92%	19.25%	17.62%

Krystal Biotech has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	4.21	-$575M	-$6.11	N/A
Krystal Biotech	$389.13M	25.77	$204.83M	$7.48	45.48

Summary

Krystal Biotech beats Ultragenyx Pharmaceutical on 10 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Regencell Bioscience has higher earnings, but lower revenue than Ultragenyx Pharmaceutical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Ultragenyx Pharmaceutical	$673M	4.21	-$575M	-$6.11	N/A

Regencell Bioscience has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Regencell Bioscience's return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ultragenyx Pharmaceutical has a consensus price target of $59.56, suggesting a potential upside of 107.10%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Regencell Bioscience has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

In the previous week, Regencell Bioscience had 10 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 22 mentions for Regencell Bioscience and 12 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Regencell Bioscience's score of 0.03 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ultragenyx Pharmaceutical beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Ultragenyx Pharmaceutical presently has a consensus price target of $59.56, indicating a potential upside of 107.10%. Cytokinetics has a consensus price target of $99.30, indicating a potential upside of 24.11%. Given Ultragenyx Pharmaceutical's higher possible upside, equities analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

Ultragenyx Pharmaceutical has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	4.21	-$575M	-$6.11	N/A
Cytokinetics	$105.82M	94.09	-$784.96M	-$6.84	N/A

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Cytokinetics. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 9 mentions for Cytokinetics. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Cytokinetics' score of 0.97 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Cytokinetics	-784.02%	N/A	-52.86%

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Ultragenyx Pharmaceutical beats Cytokinetics on 11 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Abivax?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Abivax has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Abivax is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	4.21	-$575M	-$6.11	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, Abivax has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Ultragenyx Pharmaceutical had 5 more articles in the media than Abivax. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 7 mentions for Abivax. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Abivax's score of 0.28 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abivax has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Abivax's return on equity of -99.02% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Abivax	N/A	-99.02%	-70.26%

Ultragenyx Pharmaceutical currently has a consensus price target of $59.56, indicating a potential upside of 107.10%. Abivax has a consensus price target of $130.08, indicating a potential upside of 32.15%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Ultragenyx Pharmaceutical beats Abivax on 11 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Qiagen?

Qiagen (NYSE:QGEN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

70.0% of Qiagen shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Ultragenyx Pharmaceutical had 10 more articles in the media than Qiagen. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 2 mentions for Qiagen. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Qiagen's score of 0.37 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen presently has a consensus target price of $44.71, indicating a potential upside of 20.02%. Ultragenyx Pharmaceutical has a consensus target price of $59.56, indicating a potential upside of 107.10%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.46
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Qiagen has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

Qiagen has a net margin of 19.16% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Qiagen's return on equity of 14.40% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Qiagen has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.67	$424.88M	$1.91	19.50
Ultragenyx Pharmaceutical	$673M	4.21	-$575M	-$6.11	N/A

Summary

Qiagen beats Ultragenyx Pharmaceutical on 9 of the 16 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RARE vs. The Competition

Export

Metric	Ultragenyx Pharmaceutical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.86B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-4.71	19.75	24.92	23.98
Price / Sales	4.21	330.90	528.23	109.07
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	-34.65	8.29	10.79	6.50
Net Income	-$575M	$23.85M	$3.56B	$336.88M
7 Day Performance	6.87%	2.87%	1.00%	-0.14%
1 Month Performance	22.96%	2.19%	0.42%	0.77%
1 Year Performance	-22.60%	55.48%	29.70%	28.49%

Ultragenyx Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RARE Ultragenyx Pharmaceutical	3.4083 of 5 stars	$28.76 -0.9%	$59.56 +107.1%	-21.9%	$2.86B	$673M	N/A	1,371
KRYS Krystal Biotech	2.4903 of 5 stars	$324.75 +2.1%	$324.11 -0.2%	+146.7%	$9.37B	$389.13M	43.42	210	Positive News Analyst Downgrade
RGC Regencell Bioscience	0.3967 of 5 stars	$17.09 -9.2%	N/A	-53.2%	$9.31B	N/A	N/A	10	Trending News
CYTK Cytokinetics	3.5363 of 5 stars	$71.38 +1.8%	$99.30 +39.1%	+145.1%	$8.73B	$88.04M	N/A	250	Insider Trade
ABVX Abivax	3.3435 of 5 stars	$98.26 +1.8%	$130.08 +32.4%	+1,511.0%	$7.70B	N/A	N/A	61	Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RARE) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. KRYS, RGC, CYTK, ABVX, and QGEN

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Summary

How does Ultragenyx Pharmaceutical compare to Regencell Bioscience?

Summary

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Summary

How does Ultragenyx Pharmaceutical compare to Abivax?

Summary

How does Ultragenyx Pharmaceutical compare to Qiagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. KRYS, RGC, CYTK, ABVX, and QGEN

How does Ultragenyx Pharmaceutical compare to Krystal Biotech?

Which has more volatility & risk, RARE or KRYS?

Do insiders & institutionals hold more shares of RARE or KRYS?

Do analysts prefer RARE or KRYS?

Does the media favor RARE or KRYS?

Is RARE or KRYS more profitable?

Which has better valuation & earnings, RARE or KRYS?

Summary

How does Ultragenyx Pharmaceutical compare to Regencell Bioscience?

Which has stronger earnings and valuation, RGC or RARE?

Is RGC or RARE more profitable?

Do institutionals & insiders hold more shares of RGC or RARE?

Do analysts prefer RGC or RARE?

Which has more volatility & risk, RGC or RARE?

Does the media refer more to RGC or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Cytokinetics?

Which has more risk & volatility, RARE or CYTK?

Do analysts rate RARE or CYTK?

Which has preferable earnings & valuation, RARE or CYTK?

Does the media refer more to RARE or CYTK?

Is RARE or CYTK more profitable?

Do institutionals & insiders believe in RARE or CYTK?

Summary

How does Ultragenyx Pharmaceutical compare to Abivax?

Which has higher valuation & earnings, RARE or ABVX?

Which has more risk & volatility, RARE or ABVX?

Do insiders and institutionals believe in RARE or ABVX?

Does the media prefer RARE or ABVX?

Is RARE or ABVX more profitable?

Do analysts prefer RARE or ABVX?

Summary

How does Ultragenyx Pharmaceutical compare to Qiagen?

Do insiders & institutionals have more ownership in QGEN or RARE?

Does the media favor QGEN or RARE?

Do analysts prefer QGEN or RARE?

Which has more risk and volatility, QGEN or RARE?

Is QGEN or RARE more profitable?

Which has preferable earnings and valuation, QGEN or RARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools